Newsletter FIT
Dashboard Search Watchlist Alerts Billing
SEARCH // ⌘K
Sign in Get started

Billing Watchlist

Article // Intelligence

HealthVC · Sep 24, 2026 · Martyn Eeles

What Your Cap Table Cannot Tell You

How royalties, licence payments and other asset obligations change the economics of a life-sciences investment.

Open original article View publication

What's interesting

  • Mentions HealthVC
  • Mentions Zymeworks
  • Mentions Royalty Pharma
  • Discusses Venture capital fundraising
  • Discusses licensing agreements
  • Discusses royalty structures

Engagement

Likes: 1

Comments: 0

Restacks: 0

Entities

Topics

Venture capital fundraising licensing agreements royalty structures financial modeling capital planning Equity valuation commercial diligence Startup economics

Companies

HealthVC Zymeworks Royalty Pharma Ziihera

Sponsorship

No sponsorship detected

Related articles

The Fund Fit Problem

HealthVC · HealthVC · Venture capital fundraising · Same publication

The IC Risk Problem

HealthVC · HealthVC · Venture capital fundraising · Same publication

The Ownership Problem

HealthVC · HealthVC · Venture capital fundraising · Same publication

HealthVC Summit Zurich: Why We Built the Room

HealthVC · HealthVC · Same publication

The Fund Cycle Problem

HealthVC · HealthVC · Same publication

The Money You Raised but Cannot Spend

HealthVC · HealthVC · Same publication

The Downstream Financing Problem

HealthVC · Venture capital fundraising · Same publication

Half of Duxbury’s $3 Million Revenue Gain Is Spoken For, Against $74 Million in Capital Requests

South Shore News · capital planning

SEARCH // ESC

Type to search